Project Grant HT94252510724
Award Date
9/1/25
Completion Date
8/31/28
Dollars Obligated
$817K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
The federal Project Grant award of $1,144,500.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support research by the University of Texas MD Anderson Cancer Center to investigate the PRMT3-IGF2BP1 axis-mediated epitranscriptomic reprogramming as a novel therapeutic strategy to overcome immunotherapy resistance in clear cell renal cell carcinoma (CCRCC). The award period runs from September 1, 2025, through August 31, 2028. MD Anderson, a...
The University of Texas MD Anderson Cancer Center received a $567,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on September 1, 2024, will fund research targeting myeloid mimicry in renal medullary carcinoma, with a completion date of August 31, 2027. Through this federal grant, MD Anderson Cancer Center will conduct innovative scientific studies, ranging from basic laboratory research to advanced...
The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, received a $486,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The 3-year grant, with a start date of September 30, 2023, supports research targeting the PRMT5 protein in melanoma with MTAP gene loss. The funding will enable preclinical studies, including evaluating novel treatments, to advance the understanding and...
The University of Texas MD Anderson Cancer Center received a $647,998 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award will fund research to develop image-guided, bidirectional EphB4 agonist-based therapy for ovarian cancer over a 4-year period from September 1, 2023 to August 31, 2027. MD Anderson, a comprehensive cancer treatment and research center, has extensive experience conducting basic,...
This Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Texas Southwestern Medical Center. The $1,312,000 grant, with a period of performance from July 1, 2024 to June 30, 2028, will support research on biomarkers and mechanisms of acquired resistance to immunotherapy for renal cell carcinoma. This work aims to improve understanding and treatment of this form of kidney cancer, which is a...
The University of Texas MD Anderson Cancer Center was awarded a $1,214,999 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research to identify collateral lethal targets in prostate cancer from September 1, 2021 through August 31, 2024. The Military Medical Research and Development program supports biomedical research that transforms military and public health care through innovative...
The University of Texas MD Anderson Cancer Center received a $647,990 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). This three-year grant, effective June 1, 2024, supports research to investigate cell plasticity and epigenetic reprogramming mechanisms underlying the transition of well-differentiated to de-differentiated liposarcoma. The funding will enable basic research, translational studies, and potentially future...
The University of Texas MD Anderson Cancer Center will receive $2,172,614 under a three-year Project Grant from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 2022 to September 2025 to develop an integrated genomic and therapeutic strategy for androgen-indifferent prostate cancers. The Military Medical Research and Development program supports biomedical research with the goals of improving...
The Department of the Army Medical Command awarded a $249,999 Project Grant to The University of Texas M.D. Anderson Cancer Center through the Military Medical Research and Development program. This three-year grant will fund research from September 2022 to August 2025 to revisit antiangiogenic therapy and target prostate cancer metabolism. The Military Medical Research and Development program, designated by CFDA #12.420, supports basic, applied, and advanced biomedical research with the goals...
This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $1,444,922.00 to the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct research on a novel epigenetic determinant in metastatic prostate cancer. The award period is from September 15, 2024 to September 14, 2027. MD Anderson, a comprehensive cancer research and treatment center, will utilize this funding to carry out basic,...